Alan Bash

Amministratore Delegato presso Zielbio, Inc.

52 anni

Health Technology

Consumer Services

Profilo

Alan S.
Bash is currently the Chief Executive Officer & Director at Zielbio, Inc. Prior to this, he was the President, Chief Executive Officer & Director at Checkmate Pharmaceuticals, Inc. in 2022.
He also worked as a Senior Vice President-Commercial Model Innovation at Bristol Myers Squibb Co. Mr. Bash completed his undergraduate degree at Georgetown University and earned an MBA from Columbia Business School.

Posizioni attive di Alan Bash

Società	Posizione	Inizio
Zielbio, Inc. Zielbio, Inc. Medical SpecialtiesHealth Technology Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA.	Amministratore Delegato	03/01/2023

Tutte le posizioni attive di Alan Bash

Precedenti posizioni note di Alan Bash

Società	Posizione	Fine
BRISTOL-MYERS SQUIBB COMPANY	Corporate Officer/Principal	-
CHECKMATE PHARMACEUTICALS, INC.	Amministratore Delegato	-

Vedi nel dettaglio l'esperienza di Alan Bash

Formazione di Alan Bash

Georgetown University	Undergraduate Degree
Columbia Business School	Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Alan Bash

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
BRISTOL-MYERS SQUIBB COMPANY	Health Technology

Aziende private	2
Checkmate Pharmaceuticals, Inc. Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.	Health Technology
Zielbio, Inc. Zielbio, Inc. Medical SpecialtiesHealth Technology Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA.	Health Technology